HPV detection and genotyping in past IARC FVU surveys were performed using the GP5+/6+ PCR-enzyme immunoassay (EIA), followed by reverse line blot hybridization (GP5+/6+ RLB) (11, 13, –, 15, 28), a well-validated test long considered as the standard comparator for evaluating new cervical cancer screening tests (29). This evidence concerns the gene GP5 and cervical cancer.